Stocks · News reference
Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
Pegasystems Inc (NASDAQ: PEGA) reported lower-than-expected earnings and sales, causing stocks to fall 16% in pre-market trading.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BOXABL Signs Deal That Could Cover Up To 1,500 Homes Over Three Years
BOXABL Inc. (NASDAQ:BXBL), a Nevada-based manufacturer of factory-built housing solutions designed for speed, efficiency, and attainability, today announced that it has entered into a multiyear purchase agreement with
8-K filing — BOXABL Inc. (BXBL)
Filed: 2026-08-28 AccNo: 0001493152-26-040483 Size: 481 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
BOXABL Expands Project Development Capabilities, Including Engaging Licensed General Contracting Capability In California
Move enhanced the Company's ability to bring its manufactured buildings to its customers. As part of this effort, BOXABL has engaged licensed general contracting capability in California, the first step toward the
BOXABL Launches Server Pod Concept Study For Modular, Factory-Assembled Structures For AI And Cloud Computing Infrastructure
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $46
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $40 to $46.